Alzamend Neuro Inc reports results for the quarter ended in January - Earnings Summary

Alzamend Neuro

25/03/2024 22:32

* Alzamend Neuro Inc  ALZN.OQ  reported a quarterly adjusted
loss
of 38 cents​​ per share for the quarter ended in January, higher
than the same quarter last year, when the company reported EPS
of -90 cents.  The mean expectation of two analysts for the
quarter was for a loss of 32 cents per share. Wall Street
expected results to range from -41 cents to -24 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Alzamend Neuro Inc's reported EPS for the quarter was a
loss
of 38 cents​.
    * The company reported a quarterly loss of $2.66 million.
    * Alzamend Neuro Inc shares had risen by 20.2% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 24.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Alzamend Neuro
Inc is $25.00 
This summary was machine generated from LSEG data March 25 at
10:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 31 2024      -0.32          -0.38          Missed
 Oct. 31 2023      -0.67          -0.44          Beat
 Jul. 31 2023      -0.52          -0.60          Missed
 Apr. 30 2023      -0.67          -0.45          Beat